ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum Samples

To support PK study in preclinical and clinical research, we have launched kits for the studies of CTLA-4, PD-1, and HER-2, respectively, in both humans, and common experimental animals.

Free Sample Promotion

Promotion Period:

April 1, 2018 – May 30, 2018

Apply for Free Sample Now!

Product Features

Low Background

The serum samples contain many factors that may potentially interfere with the indirect ELISA result. This is the major reason for the background issue (Fig. 1A). Therefore, a series of testing need to be performed to determine the minimum required dilution (MRD) before an experiment can be conducted. This can be time consuming and the results can vary. On the other hand, the competitive ELISA method we employed for our kit does not have a background issue. As shown in Fig 1B, dilutions up to 1:5 does not produce any background at all.

Figure 1. Comparison between Indirect ELISA and antibody-directed competitive ELISA for PD1 mAb detection in patient samples. A: Indirect ELISA; B: antibody-directed competitive ELISA.??

<<< Click for more information

Application

The assay kits can be used for studies of any mAbs share similar binding domain as our tracer biotinylated antibody.

For example, with our Anti-PD-1 mAb kit for human serum samples (Cat. No. EPH-V1), we have successfully measured five different anti-PD1 mAbs that are either on the market already or being tested in clinical trials.